First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report.

Saved in:
Bibliographic Details
Title: First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report.
Authors: Wang K; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Taslic CA; Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., de Groot P; Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Parma MA; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Paula AG; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Caranto M; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shah K; Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bose M; Cancer System Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ruoff C; Graduate School of Biomedical Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karacosta LG; Cancer System Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Byers LA; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gay CM; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Heymach JV; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang B; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2025 Dec 12; Vol. 7 (2), pp. 100941. Date of Electronic Publication: 2025 Dec 12 (Print Publication: 2026).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3643
DOI:10.1016/j.jtocrr.2025.100941